Galsky MD - Search Results

1

Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma.

Agarwal N, Apolo AB, Tsao CK, Lee KM, Godbold JH, Soto R, Poole A, Gimpel-Tetra K, Lowe N, Oh WK, Galsky MD. Agarwal N, et al. Among authors: galsky md. Oncologist. 2014 Sep;19(9):915-6. doi: 10.1634/theoncologist.2014-0153. Epub 2014 Jul 22. Oncologist. 2014. PMID: 25052451 Free PMC article. Clinical Trial.

2

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.

Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, Martone L, Curley T, Delacruz A, Scher HI, Kelly WK. Galsky MD, et al. J Clin Oncol. 2005 Mar 1;23(7):1439-46. doi: 10.1200/JCO.2005.09.042. J Clin Oncol. 2005. PMID: 15735119 Clinical Trial.

3

The role of taxanes in the management of bladder cancer.

Galsky MD. Galsky MD. Oncologist. 2005 Nov-Dec;10(10):792-8. doi: 10.1634/theoncologist.10-10-792. Oncologist. 2005. PMID: 16314289 Free article. Review.

4

A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.

Rosenberg JE, Galsky MD, Rohs NC, Weinberg VK, Oh WK, Kelly WK, Small EJ. Rosenberg JE, et al. Among authors: galsky md. Cancer. 2006 Jan 1;106(1):58-62. doi: 10.1002/cncr.21559. Cancer. 2006. PMID: 16329138 Free article.

5

Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma.

Galsky MD, Mironov S, Iasonos A, Scattergood J, Boyle MG, Bajorin DF. Galsky MD, et al. Invest New Drugs. 2007 Jun;25(3):265-70. doi: 10.1007/s10637-006-9020-9. Epub 2006 Dec 5. Invest New Drugs. 2007. PMID: 17146733 Clinical Trial.

6

Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function.

Galsky MD, Iasonos A, Mironov S, Scattergood J, Boyle MG, Bajorin DF. Galsky MD, et al. Cancer. 2007 Feb 1;109(3):549-55. doi: 10.1002/cncr.22454. Cancer. 2007. PMID: 17200962 Free article. Clinical Trial.

7

Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract.

Galsky MD, Iasonos A, Mironov S, Scattergood J, Donat SM, Bochner BH, Herr HW, Russo P, Boyle MG, Bajorin DF. Galsky MD, et al. Urology. 2007 Feb;69(2):255-9. doi: 10.1016/j.urology.2006.10.029. Urology. 2007. PMID: 17320659 Clinical Trial.

8

Cabazitaxel.

Galsky MD, Dritselis A, Kirkpatrick P, Oh WK. Galsky MD, et al. Nat Rev Drug Discov. 2010 Sep;9(9):677-8. doi: 10.1038/nrd3254. Nat Rev Drug Discov. 2010. PMID: 20811375 No abstract available.

9

A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy.

Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg C, Bajorin DF, Bellmunt J. Galsky MD, et al. Lancet Oncol. 2011 Mar;12(3):211-4. doi: 10.1016/S1470-2045(10)70275-8. Lancet Oncol. 2011. PMID: 21376284 No abstract available.

10

Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.

Galsky MD, Chen GJ, Oh WK, Bellmunt J, Roth BJ, Petrioli R, Dogliotti L, Dreicer R, Sonpavde G. Galsky MD, et al. Ann Oncol. 2012 Feb;23(2):406-10. doi: 10.1093/annonc/mdr156. Epub 2011 May 4. Ann Oncol. 2012. PMID: 21543626 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

421 results

Search Page

Filters